China biotech industry gets talent injection

A shift from copycat drugs to a research-driven biotech industry is attracting expat scientists back home to help meet the challenges of an ageing population.

When Dr Yang Dajun who is working on curing diseases related to aging, chose to return to China in 2005 to launch his own biopharmaceutical start-up after almost two decades in the US, he said the decision wasn’t easy.

“It was a bit difficult as at that time China’s biotech industry was at a very early stage. A lot of things were not available, especially the financial environment. But I’m not regretting the decision,” Yang, co-founder and chief executive of Ascentage Pharma, told FinanceAsia in an interview.

Yang went to the US in 1986 to study oncology broadly, the prevention, diagnosis and treatment of cancer....

¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team subscription (2-5 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team subscription (2-5 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222